In this final episode of the year, Ted Slafsky, Will Newton and Shannon Young unpack the most significant developments in the 340B program in both recent weeks and 2024. From the escalating legal battles over proposed 340B rebate models and pivotal state legislation to key court decisions and congressional activity, the team provides in-depth analysis of the year’s top stories. They also share insights into what these shifts could mean for stakeholders and preview the issues expected to dominate the 340B landscape in 2025.

Key Topics Covered: 

The Rebate Model Debate Will provides an update on the escalating legal battle over rebate models, including HRSA’s recent enforcement threats against Sanofi, and how they compare to Johnson & Johnson, Eli Lilly, and Bristol-Myers Squibb’s rebate proposals. 

State-Level Action on 340B Contract Pharmacy Laws Will discusses the latest state-based actions on 340B, including Michigan’s bid to pass a contract pharmacy access law, the Kansas attorney general’s unexpected legal interpretation of that state’s contract pharmacy law and a recent federal district court ruling in West Virginia in favor of the drug industry. That West Virginia ruling sharply contrasted with earlier court decisions favoring state laws in Arkansas, Louisiana and Mississippi.

Federal Legislative Changes and Key Lawmakers Shannon provides an update on the incoming 119th Congress. She discusses how leadership shifts on the House Energy and Commerce Committee could influence 340B policy in 2025 and beyond. Ted discusses the House lawmakers who could play key roles in 340B policymaking. They include members who have raised serious concerns with the program such as Reps. Buddy Carter (R-GA) and Harshbarger (R-TN) and strong program supporters, like Reps. Dusty Johnson (R-SD), Doris Matsui (D-CA) and Diana DeGette (D-CO).

Top Stories of 2024 The episode wraps with a look back at the most-read 340B stories of the year. From the rebate model saga and states’ 340B legislative efforts, to the Inflation Reduction Act’s impact on 340B, the team reflects on the growing importance of state-level action and anticipates continued court battles and policy debates in 2025.

What’s Next for Inside 340B Report

In future episodes, the team will provide an inside look at the issues impacting the stakeholders in the 340B program. Listen to fascinating conversations between 340B Report editors and reporters on what they are covering and why it is important. 

Stay tuned for more episodes every other week! 🎧 Subscribe to Inside 340B Report on your favorite podcast platform and follow us on YouTube for video discussions.

Special thanks to 340B Report Ultra Diamond sponsors who made this episode possible including: AIDS Healthcare Foundation, The Alinea Group, Avita Care Solutions, Maxor, RxParadigm, RxStrategies and Verity Solutions.

Thank you for joining us on this journey. We look forward to bringing you valuable insights and discussions on the 340B program. For more information, visit 340BReport.com.

Special discount for YouTube and podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.